Theratechnologies to Make Oral Presentation on Oncology Platform During AACR Virtual Annual Meeting

NEXT STORY
The Christ Hospital Health Network Partners with Air Methods to Serve Greater Cincinnati Area
PREV STORY
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

author_avatar
NASDAQ Market News

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

author_avatar
NASDAQ Market News

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

author_avatar
NASDAQ Market News